[ANGO] AngioDynamics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 16.86 Change: 0.06 (0.36%)
Ext. hours: Change: 0 (0%)

chart ANGO

Refresh chart

Description: AngioDynamics, Inc. designs, manufactures, and sells medical, surgical, and diagnostic devices. The company offers manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; and venous products, including laser system products used in endovascular laser procedures to treat superficial venous diseases, as well as sclerosing drugs that are used in the treatment of small uncomplicated varicose veins of the lower extremities. It also provides angiographic catheters and guidewires used during peripheral vascular interventional procedures; venous drainage cannula intended for use as a venous drainage cannula during extracorporeal bypass and cardiopulmonary bypass circuit intended for use in procedures requiring extracorporeal circulatory support; and drainage products that drain abscesses and other fluid pockets. In addition, the company offers

Fundamental Ratios
Shares Outstanding EPS-0.78 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -7.93% Sales Growth - Q/Q-6.03% P/E-20.47
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-0.47% ROE-0.67% ROI-0.51%
Current Ratio2.64 Quick Ratio1.48 Long Term Debt/Equity1.45 Debt Ratio0.11
Gross Margin49.63% Operating Margin0.35% Net Profit Margin-1.02% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities640 K Cash From Investing Activities-12.04 M Cash From Operating Activities15.44 M Gross Profit37.85 M
Net Profit-4.26 M Operating Profit-10.15 M Total Assets783.14 M Total Current Assets157.29 M
Total Current Liabilities59.69 M Total Debt148.91 M Total Liabilities239.38 M Total Revenue86.6 M
Technical Data
High 52 week23.46 Low 52 week15.71 Last close22.91 Last change-0.39%
RSI68.83 Average true range0.57 Beta0.9 Volume61.4 K
Simple moving average 20 days3.08% Simple moving average 50 days8.1% Simple moving average 200 days21.36%
Performance Data
Performance Week-2.34% Performance Month9.15% Performance Quart9.04% Performance Half34.76%
Performance Year39.19% Performance Year-to-date13.81% Volatility daily1.45% Volatility weekly3.24%
Volatility monthly6.63% Volatility yearly22.98% Relative Volume208.94% Average Volume193.36 K
New High New Low


2019-09-09 08:00:00 | AngioDynamics Awarded Premier’s Nationally Outsourced Implantable Infusion Port Agreement

2019-09-05 16:01:00 | AngioDynamics to Report Fiscal 2020 First Quarter Financial Results on October 3, 2019

2019-08-15 11:05:56 | Calculating The Intrinsic Value Of AngioDynamics, Inc. NASDAQ:ANGO

2019-08-09 09:30:01 | AngioDynamics ANGO Down 8.9% Since Last Earnings Report: Can It Rebound?

2019-07-31 16:01:00 | AngioDynamics Announces Appointment of Former Johnson & Johnson Executive Karen Licitra to its Board of Directors

2019-07-25 12:48:03 | AngioDynamics Inc ANGO Files 10-K for the Fiscal Year Ended on May 31, 2019

2019-07-23 16:01:00 | AngioDynamics to Present at the Canaccord Genuity Growth Conference

2019-07-11 11:07:03 | AngioDynamics ANGO Q4 Earnings Miss, Revenues Top Estimates

2019-07-10 22:23:22 | AngioDynamics ANGO Q4 2019 Earnings Call Transcript

2019-07-10 17:57:26 | Edited Transcript of ANGO earnings conference call or presentation 10-Jul-19 12:00pm GMT

2019-07-10 16:46:10 | AngioDynamics completes $100 million turnaround

2019-07-10 08:25:12 | AngioDynamics ANGO Lags Q4 Earnings Estimates

2019-07-10 07:29:46 | Is AngioDynamics, Inc.'s NASDAQ:ANGO CEO Paid At A Competitive Rate?

2019-07-10 07:00:00 | AngioDynamics Reports Fiscal 2019 Fourth Quarter and Full-Year Financial Results

2019-07-10 06:00:00 | AngioDynamics, Inc. to Host Earnings Call

2019-07-09 15:51:09 | Q4 Earnings Outlook For AngioDynamics

2019-07-06 14:45:22 | The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings

2019-07-03 10:30:02 | AngioDynamics ANGO Reports Next Week: Wall Street Expects Earnings Growth

2019-06-27 11:33:13 | AngioDynamics' bold move: get smaller for now

2019-06-25 21:24:27 | Is AngioDynamics, Inc. ANGO A Good Stock To Buy?

2019-06-20 16:01:00 | AngioDynamics to Report Fiscal 2019 Fourth Quarter and Full-Year Financial Results on July 10, 2019

2019-06-06 06:00:00 | AngioDynamics moving 125 employees into downtown Glens Falls

2019-06-05 10:05:02 | AngioDynamics Divests NAMIC Portfolio to Medline Industries

2019-06-04 16:01:00 | AngioDynamics to Present at the Raymond James Life Sciences and MedTech Conference

2019-06-03 16:01:00 | AngioDynamics Completes Sale of NAMIC® Fluid Management Portfolio to Medline Industries, Inc.

2019-05-28 08:00:00 | AngioDynamics to Ring NASDAQ Closing Bell to Celebrate the 15th Anniversary of its Listing on the Exchange

2019-05-23 07:33:11 | AngioDynamics IDE Application for NanoKnife Gets FDA Nod

2019-05-22 08:00:00 | AngioDynamics Receives FDA Approval to Initiate Pilot Study for the Use of NanoKnife® to Treat Prostate Cancer

2019-05-13 08:00:00 | AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer

2019-05-09 11:27:09 | Here’s What Hedge Funds Think About AngioDynamics, Inc. ANGO

2019-05-02 09:30:01 | Why Is AngioDynamics ANGO Down 12.1% Since Last Earnings Report?

2019-04-18 07:42:58 | The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio

2019-04-17 19:37:54 | AngioDynamics will sell Namic business for $167.5 million

2019-04-17 16:05:00 | AngioDynamics Announces Agreement to Sell NAMIC® Fluid Management Business to Medline Industries, Inc. for $167.5 Million

2019-04-17 12:13:46 | Why AngioDynamics, Inc.’s NASDAQ:ANGO Return On Capital Employed Might Be A Concern

2019-04-17 08:01:00 | AngioDynamics’ DIRECT Clinical Study Receives Institutional Review Board Approval for the Treatment of Stage III Pancreatic Cancer

2019-04-03 10:32:02 | AngioDynamics' ANGO Q3 Earnings & Revenues Lag Estimates

2019-04-02 20:45:00 | AngioDynamics ANGO Q3 2019 Earnings Conference Call Transcript

2019-04-02 13:26:51 | Edited Transcript of ANGO earnings conference call or presentation 2-Apr-19 12:00pm GMT

2019-04-02 10:20:02 | AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study

2019-04-02 08:15:12 | AngioDynamics ANGO Lags Q3 Earnings and Revenue Estimates

2019-04-02 07:09:31 | AngioDynamics: Fiscal 3Q Earnings Snapshot

2019-04-02 07:00:00 | AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results

2019-04-02 06:00:00 | AngioDynamics, Inc. to Host Earnings Call

2019-04-01 16:01:00 | AngioDynamics to Present at the Needham Healthcare Conference

2019-04-01 06:00:00 | AngioDynamics Receives FDA Approval to Initiate NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer

2019-03-28 18:48:00 | CORRECTING and REPLACING OARtrac® Radiation Dose Monitoring System Receives Expanded FDA Clearance for Electron Radiation Therapy

2019-03-26 10:30:02 | Analysts Estimate AngioDynamics ANGO to Report a Decline in Earnings: What to Look Out for

2019-03-12 16:01:00 | AngioDynamics to Report Fiscal 2019 Third Quarter Financial Results on April 2, 2019

2019-03-12 10:58:02 | Avanos AVNS Q4 Earnings Beat, Revenues Miss, Shares Down